S&P 500   3,851.85
DOW   31,188.38
QQQ   323.77
pixel
S&P 500   3,851.85
DOW   31,188.38
QQQ   323.77
pixel
S&P 500   3,851.85
DOW   31,188.38
QQQ   323.77
pixel
S&P 500   3,851.85
DOW   31,188.38
QQQ   323.77
pixel
Log in
NASDAQ:VYGR

Voyager Therapeutics Stock Forecast, Price & News

$8.87
+0.20 (+2.31 %)
(As of 01/20/2021 12:00 AM ET)
Add
Compare
Today's Range
$8.71
Now: $8.87
$8.91
50-Day Range
$7.15
MA: $8.13
$9.28
52-Week Range
$6.26
Now: $8.87
$14.62
Volume273,014 shs
Average Volume415,253 shs
Market Capitalization$332.32 million
P/E RatioN/A
Dividend YieldN/A
Beta1.8
Voyager Therapeutics, Inc., a clinical-stage gene therapy company, focuses on the development of treatments for patients suffering from severe neurological diseases. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1b clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyotrophic lateral sclerosis; VY-HTT01 for Huntington's disease; VY-FXN01 for Friedreich's ataxia; Tau program for the treatment of tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia; and alpha-synuclein program for synucleinopathies, Parkinson's disease, Lewy Body Dementia, and multiple system atrophy. The company has strategic collaboration agreements with the University of Massachusetts; and ClearPoint Neuro, Inc., as well as collaborations with Brammer Bio and Fujifilm Diosynth Biotechnologies to support the development of its gene therapy programs. It also has a collaboration and license agreement with Neurocrine Biosciences, Inc. for the research, development, and commercialization of adeno-associated virus-based gene therapy products. Voyager Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Voyager Therapeutics logo

MarketRank

Overall MarketRank

1.70 out of 5 stars

Medical Sector

207th out of 1,928 stocks

Biological Products, Except Diagnostic Industry

27th out of 177 stocks

Analyst Opinion: 4.3Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:VYGR
CUSIPN/A
Phone857-259-5340
Employees185

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$104.39 million
Book Value$2.68 per share

Profitability

Net Income$-43,600,000.00

Miscellaneous

Market Cap$332.32 million
Next Earnings Date3/2/2021 (Estimated)
OptionableOptionable
$8.87
+0.20 (+2.31 %)
(As of 01/20/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive VYGR News and Ratings via Email

Sign-up to receive the latest news and ratings for VYGR and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Voyager Therapeutics (NASDAQ:VYGR) Frequently Asked Questions

How has Voyager Therapeutics' stock price been impacted by Coronavirus (COVID-19)?

Voyager Therapeutics' stock was trading at $9.43 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, VYGR stock has decreased by 5.9% and is now trading at $8.87.
View which stocks have been most impacted by COVID-19
.

Is Voyager Therapeutics a buy right now?

12 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Voyager Therapeutics in the last twelve months. There are currently 6 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Voyager Therapeutics stock.
View analyst ratings for Voyager Therapeutics
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Voyager Therapeutics?

Wall Street analysts have given Voyager Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Voyager Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What is Doug Parker's approval rating as Voyager Therapeutics' CEO?

1,428 employees have rated Voyager Therapeutics CEO Doug Parker on Glassdoor.com. Doug Parker has an approval rating of 59% among Voyager Therapeutics' employees. This puts Doug Parker in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

When is Voyager Therapeutics' next earnings date?

Voyager Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, March 2nd 2021.
View our earnings forecast for Voyager Therapeutics
.

How were Voyager Therapeutics' earnings last quarter?

Voyager Therapeutics, Inc. (NASDAQ:VYGR) posted its quarterly earnings data on Monday, November, 9th. The company reported $2.27 EPS for the quarter, beating the Zacks' consensus estimate of ($0.19) by $2.46. The business earned $117.84 million during the quarter, compared to analysts' expectations of $43.34 million. Voyager Therapeutics had a negative return on equity of 66.46% and a negative net margin of 60.61%.
View Voyager Therapeutics' earnings history
.

What price target have analysts set for VYGR?

12 equities research analysts have issued 1 year price targets for Voyager Therapeutics' stock. Their forecasts range from $10.00 to $26.00. On average, they expect Voyager Therapeutics' stock price to reach $15.38 in the next year. This suggests a possible upside of 73.4% from the stock's current price.
View analysts' price targets for Voyager Therapeutics
or view Wall Street analyst' top-rated stocks.

Who are some of Voyager Therapeutics' key competitors?

What other stocks do shareholders of Voyager Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Voyager Therapeutics investors own include Micron Technology (MU), REGENXBIO (RGNX), NVIDIA (NVDA), Sorrento Therapeutics (SRNE), TG Therapeutics (TGTX), Amarin (AMRN), CRISPR Therapeutics (CRSP), Inovio Pharmaceuticals (INO), Sangamo Therapeutics (SGMO) and Editas Medicine (EDIT).

Who are Voyager Therapeutics' key executives?

Voyager Therapeutics' management team includes the following people:
  • Mr. G. Andre Turenne, CEO, Pres & Director (Age 46, Pay $797.68k)
  • Mr. Robert W. Hesslein, Sr. VP & Gen. Counsel (Age 67, Pay $544.4k)
  • Dr. Omar Khwaja M.D., Ph.D., Chief Medical Officer and Head of R&D (Age 50, Pay $698.59k)
  • Dr. Steven M. Paul M.D., Exec. Science Advisor & Director (Age 69, Pay $333.09k)
  • Dr. Krystof Bankiewicz M.D., Ph.D., Founder
  • Dr. Guangping Gao, Founder
  • Dr. Mark A. Kay, Founder (Age 62)
  • Dr. Phillip D. Zamore, Founder
  • Ms. Allison Dorval, CFO & Principal Accounting Officer (Age 44)
  • Mr. Paul Cox, VP of Investor Relations

What is Voyager Therapeutics' stock symbol?

Voyager Therapeutics trades on the NASDAQ under the ticker symbol "VYGR."

How do I buy shares of Voyager Therapeutics?

Shares of VYGR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Voyager Therapeutics' stock price today?

One share of VYGR stock can currently be purchased for approximately $8.87.

How big of a company is Voyager Therapeutics?

Voyager Therapeutics has a market capitalization of $332.32 million and generates $104.39 million in revenue each year. The company earns $-43,600,000.00 in net income (profit) each year or ($1.21) on an earnings per share basis. Voyager Therapeutics employs 185 workers across the globe.

What is Voyager Therapeutics' official website?

The official website for Voyager Therapeutics is www.voyagertherapeutics.com.

How can I contact Voyager Therapeutics?

Voyager Therapeutics' mailing address is 75 SIDNEY STREET, CAMBRIDGE MA, 02139. The company can be reached via phone at 857-259-5340 or via email at [email protected]

This page was last updated on 1/21/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.